Salinas-Souza et al. (2010) investigated the genotype frequencies of GSTM1, GSTT1 and GSTM3 genes in 80 osteosarcoma patients and 160 normal control participants, and also the influence of these polymorphisms on the clinical outcome of osteosarcoma patients. They concluded that GST polymorphisms may have a role in treatment response and osteosarcoma progression (Salinas-Souza et al., 2010). This evidence concerns the gene GSTM1 and osteosarcoma.